▲ S&P 500 +---% | ▲ Stock Advisor +---% Join The Motley Fool

Accessibility Log In Help

Daily Stock Gainers Daily Stock Losers Most Active Stocks

Daily Stock Gainers Daily Stock Losers Most Active Stocks

Todd Campbell

tmfebcapital

@ebcapital

Todd has been helping buy side portfolio managers as an independent researcher for over a decade. In 2003, Todd founded E.B. Capital Markets, LLC, a research firm providing action oriented ideas to professional investors. Todd has provided insight to a variety of publications, including SmartMoney, Barron's, and CNN/fn.

Recent Articles by Todd Campbell

Oct 22, 2013 by Todd Campbell

Are Drug Stocks Too Expensive?

Health care stocks were strong performers in the third quarter. Given the move higher, have drug stocks become too pricey?

Oct 22, 2013 by Todd Campbell

Congress Fails Medical Device Stocks

The budget impasse may be resolved for now, but device companies failed to win relief from a 2.3% tax designed to help pay for the Patient Protection and Affordable Care Act.

Oct 21, 2013 by Todd Campbell

Is Regeneron a Better Buy Than Celgene?

Biotech companies Regeneron and Celgene are treating investors to big returns this year. But, is one a better buy than another?

Oct 21, 2013 by Todd Campbell

Better Buy: Walgreen, CVS, or Rite Aid?

In the competitive retail pharmacy market, three of the biggest players -- Rite Aid, Walgreen, and CVS -- face off for market share. Is one a better buy than the other?

Oct 17, 2013 by Todd Campbell

Quest Diagnostics Threatens Myriad's Grip on BRCA Tests

Lab giant Quest's new BRCA genetic test poses the biggest challenge yet to Myriad's BRACAnalysis.

Oct 16, 2013 by Todd Campbell

Worried About Health Care Reform? Consider AmerisourceBergen

The Patient Protection and Affordable Care Act is creating lots of questions for investors. But drug distributors like AmerisourceBergen are likely to see solid tailwinds as a growing insured population drives prescription growth.

Oct 15, 2013 by Todd Campbell

You Shouldn't Ignore Gilead's Idelalisib

Gilead Sciences is widely known for its HIV drug portfolio and for its high-profile hep-C drug sofosbuvir. But it also has a potential winner with idelalisib, a blood cancer drug with a promising future.

Oct 14, 2013 by Todd Campbell

Why You Shouldn't Sell Insurers as Obamacare Exchanges Open

Affordable Care Act exchanges are open for business. With insurers' profits at risk, should investors fear them?

Oct 11, 2013 by Todd Campbell

Sarepta Drops -- Is There Reason to Sell?

After rallying on news that a competitor's drug failed in late-stage trials, Sarepta shares are falling. Does this present an opportunity, or is this a new trend lower?

Oct 7, 2013 by Todd Campbell

Myriad Genetics Changes How Doctors Treat Patients

Innovation in targeted cancer therapies is transforming how doctors evaluate and treat patients. That's creating opportunity for Myriad Genetics, a maker of genetic testing solutions.

Oct 4, 2013 by Todd Campbell

Can Celgene Deliver on Its High Hopes for Apremilast?

Celgene believes apremilast offers new hope for psoriasis patients. But will the drug give the the biotech another blockbuster?

Oct 3, 2013 by Todd Campbell

1 Drug That Could Reshape Breast Cancer Treatment

Biomarin hopes phase 3 trials of BMN-673 will bring new hope to a subset of breast cancer patients.

Sep 28, 2013 by Todd Campbell

Yervoy Battles Melanoma, but Can It Become a Blockbuster?

Bristol-Myers Squibb's Yervoy is succeeding as a first-line treatment in melanoma. But can the drug hold off new competitors and expand its label to become a blockbuster drug?

Sep 26, 2013 by Todd Campbell

How Johnson & Johnson Plans to Win the Prostate Cancer Battle

J&J faces stiff competition in the prostate cancer market from drugs like Xtandi and up-and-comer drugs from Exelixis and OncoGenex. Will J&J be able to maintain its leadership?

Sep 26, 2013 by Todd Campbell

How AbbVie Plans to Survive After Humira

AbbVie's licensing deal with Ablynx boosts its pipeline, but will Ablynx's ALX-0061 help AbbVie keep market share once blockbuster Humira loses patent protection?

Sep 24, 2013 by Todd Campbell

Baby Boomers Are Driving Thor Higher

RV's are enjoying a comeback as retirees take to the roads again. That's good news for market leader Thor Industries plans to double-down on the industry

Sep 20, 2013 by Todd Campbell

Can Xtandi Become the Go-To Prostate Drug?

A slew of new prostate cancer drugs offer treatment options for advance prostate cancer patients. But Xtandi could become a solution for early stage too.

Sep 19, 2013 by Todd Campbell

Polaris Bets Indian Motorcycles Will Rev up Profit

The brand best known for snowmobiles and ATVs is doubling down on its efforts to wrestle motorcycle market share from Harley Davidson.

Sep 17, 2013 by Todd Campbell

Will the Exelixis Hype Catch Up to Its Valuation?

Investors have high hopes for Exelixis' cancer drug Cometriq. But whether it can grow into its current valuation remains to be seen.

Sep 12, 2013 by Todd Campbell

1 Drug Dramatically Reshaping Pancreatic Cancer Treatment

Celgene already has a blockbuster drug with Revlimid. Does it have another in Abraxane?

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services